Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics
Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for…
Lucid Diligence Brief: R1 Therapeutics $77.5 million Series A to treat hyperphosphatemia in CKD dialysis
Lucid Diligence Brief: R1 Therapeutics $77.5 million Series A to treat…
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide collaboration
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide…
Lucid Diligence Brief: Eli Lilly $500 million South Korea biopharma pledge
Lucid Diligence Brief: Eli Lilly $500 million South Korea biopharma pledge…
Lucid Diligence Brief: Cognito Therapeutics $105 million Series C
Lucid Diligence Brief: Cognito Therapeutics $105 million Series C Professional…
Lucid Diligence Brief: Teva and Blackstone Life Sciences $400m duvakitug financing
Lucid Diligence Brief: Teva and Blackstone Life Sciences $400m duvakitug…
Lucid Diligence Brief: Poplar Therapeutics $95 million Series A
Lucid Diligence Brief: Poplar Therapeutics $95 million Series A extension…
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”…
Lucid Diligence Brief: BioNTech DualityBio BNT324 Phase 3 mCRPC
Lucid Diligence Brief: BioNTech DualityBio BNT324 Phase 3 mCRPC Professional…
ESGO 2026 Preview: Key Gynaecological Oncology Highlights to Watch
ESGO 2026 at a Glance Get ready for ESGO 2026. LucidQuest’s preview brings…
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics…
Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology
Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology…